You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSulfinpyrazone
Accession NumberDB01138  (APRD00620)
TypeSmall Molecule
GroupsApproved
DescriptionA uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. [PubChem]
Structure
Thumb
Synonyms
1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine
1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione
4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione
Anturane (tn)
Sulfinpyrazone
Sulfoxyphenylpyrazolidine
External Identifiers
  • USAF GE-13
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Antazone Tab 100mgTablet100 mgOralIcn Canada Ltd.1980-12-312005-04-26Canada
Antazone Tab 200mgTablet200 mgOralIcn Canada Ltd.1980-12-312005-04-26Canada
Anturan 100mgTablet100 mgOralNovartis Pharmaceuticals Canada Inc1959-12-311999-08-04Canada
Anturan 200mgTablet200 mgOralNovartis Pharmaceuticals Canada Inc1961-12-311999-08-04Canada
Novo-pyrazone Tab 100mgTablet100 mgOralNovopharm Limited1979-12-312005-08-10Canada
Novo-pyrazone Tab 200mgTablet200 mgOralNovopharm Limited1979-12-312005-08-10Canada
Nu-sulfinpyrazone Tab 100mgTablet100 mgOralNu Pharm Inc1993-12-312008-02-20Canada
Nu-sulfinpyrazone Tab 200mgTablet200 mgOralNu Pharm Inc1993-12-312012-09-04Canada
SulfinpyrazoneTablet200 mgOralAa Pharma Inc1978-12-31Not applicableCanada
Sulfinpyrazone 100 TabTablet100 mgOralPro Doc Limitee1979-12-312003-07-31Canada
Sulfinpyrazone 200 TabTablet200 mgOralPro Doc Limitee1979-12-312003-07-31Canada
Sulfinpyrazone Tablets 100mgTablet100 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Sulfinpyrazone Tablets 200mgTablet200 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Sulfinpyrazone Tab 100mgTablet100 mgOralApotex Inc1978-12-312008-02-19Canada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnturaneNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV6OFU47K3W
CAS number57-96-5
WeightAverage: 404.482
Monoisotopic: 404.119463206
Chemical FormulaC23H20N2O3S
InChI KeyMBGGBVCUIVRRBF-UHFFFAOYSA-N
InChI
InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
IUPAC Name
4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
SMILES
O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of gout and gouty arthritis.
Structured Indications
PharmacodynamicsSulfinpyrazone's pharmacologic activity is the potentiation of the urinary excretion of uric acid. It is useful for reducing the blood urate levels in patients with chronic tophaceous gout and acute intermittent gout, and for promoting the resorption of tophi.
Mechanism of actionSulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. This is likely done through inhibition of the urate anion transporter (hURAT1) as well as the human organic anion transporter 4 (hOAT4). Sulfinpyrazone is not intended for the treatment of acute attacks because it lacks therapeutically useful analgesic and anti-inflammatory effects. Sulfinpyrazone and its sulfide metabolite possess COX inhibitory effects. Sulfinpyrazone has also been shown to be a UDP-glucuronsyltransferase inhibitor and a very potent CYP2C9 inhibitor. Sulfinpyrazone is also known to be a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor as well as an inhibitor of several multridrug resistance proteins (MRPs).
TargetKindPharmacological actionActionsOrganismUniProt ID
Multidrug resistance-associated protein 1Proteinyes
inhibitor
HumanP33527 details
Canalicular multispecific organic anion transporter 1Proteinyes
inhibitor
HumanQ92887 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding98-99%
Metabolism
SubstrateEnzymesProduct
Sulfinpyrazone
Sulfinpyrazone sulfideDetails
Sulfinpyrazone
Sulfinpyrazone sulfoneDetails
Route of eliminationNot Available
Half lifeApproximately 4-6 hours
ClearanceNot Available
ToxicitySymptoms of overdose include nausea, vomiting, diarrhea, epigastric pain, ataxia, labored respiration, convulsions, coma. Possible symptoms, seen after overdosage with other pyrazolone derivatives: anemia, jaundice, and ulceration.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Sulfinpyrazone.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sulfinpyrazone.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Sulfinpyrazone.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Sulfinpyrazone.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Sulfinpyrazone.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
AmiodaroneThe metabolism of Sulfinpyrazone can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Sulfinpyrazone.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Sulfinpyrazone.Approved
AprepitantThe serum concentration of Sulfinpyrazone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Sulfinpyrazone.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
AtazanavirThe metabolism of Sulfinpyrazone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Sulfinpyrazone.Approved
AtomoxetineThe metabolism of Sulfinpyrazone can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
BexaroteneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Sulfinpyrazone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Sulfinpyrazone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sulfinpyrazone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sulfinpyrazone.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Sulfinpyrazone.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Sulfinpyrazone.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Sulfinpyrazone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Sulfinpyrazone.Approved
CapecitabineThe metabolism of Sulfinpyrazone can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Sulfinpyrazone can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Sulfinpyrazone.Approved
CelecoxibThe metabolism of Sulfinpyrazone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Sulfinpyrazone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Sulfinpyrazone.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
CholecalciferolThe metabolism of Sulfinpyrazone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Sulfinpyrazone.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Sulfinpyrazone.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Sulfinpyrazone.Approved
ClarithromycinThe metabolism of Sulfinpyrazone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Sulfinpyrazone can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Sulfinpyrazone.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Sulfinpyrazone.Approved
ClopidogrelThe metabolism of Sulfinpyrazone can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Sulfinpyrazone.Approved
CobicistatThe metabolism of Sulfinpyrazone can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Sulfinpyrazone.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Sulfinpyrazone.Approved
ConivaptanThe serum concentration of Sulfinpyrazone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sulfinpyrazone.Approved
CrizotinibThe metabolism of Sulfinpyrazone can be decreased when combined with Crizotinib.Approved
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Sulfinpyrazone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateSulfinpyrazone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Sulfinpyrazone.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Sulfinpyrazone.Approved
DarunavirThe metabolism of Sulfinpyrazone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Sulfinpyrazone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Sulfinpyrazone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Sulfinpyrazone.Approved
DeferasiroxThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Sulfinpyrazone can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Sulfinpyrazone.Approved, Illicit, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Sulfinpyrazone.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sulfinpyrazone.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Sulfinpyrazone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Sulfinpyrazone.Approved
DihydroergotamineThe metabolism of Sulfinpyrazone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Sulfinpyrazone.Illicit
DiltiazemThe metabolism of Sulfinpyrazone can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Sulfinpyrazone.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Sulfinpyrazone.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
DoxycyclineThe metabolism of Sulfinpyrazone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Sulfinpyrazone can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Sulfinpyrazone.Approved
EfavirenzThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
EnzalutamideThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
ErythromycinThe metabolism of Sulfinpyrazone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Sulfinpyrazone.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Sulfinpyrazone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sulfinpyrazone.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be decreased when combined with Sulfinpyrazone.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Sulfinpyrazone.Approved
EtravirineThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Sulfinpyrazone.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Sulfinpyrazone.Approved
FelodipineThe metabolism of Sulfinpyrazone can be decreased when combined with Felodipine.Approved, Investigational
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Sulfinpyrazone.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Sulfinpyrazone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Sulfinpyrazone.Approved
FloxuridineThe metabolism of Sulfinpyrazone can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Fluconazole.Approved
FluindioneThe metabolism of Fluindione can be decreased when combined with Sulfinpyrazone.Investigational
FluorouracilThe metabolism of Sulfinpyrazone can be decreased when combined with Fluorouracil.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Sulfinpyrazone.Approved
FluvastatinThe metabolism of Sulfinpyrazone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Sulfinpyrazone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Sulfinpyrazone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sulfinpyrazone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Sulfinpyrazone can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Sulfinpyrazone can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Sulfinpyrazone.Approved
GemfibrozilThe metabolism of Sulfinpyrazone can be decreased when combined with Gemfibrozil.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Sulfinpyrazone.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Sulfinpyrazone.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Sulfinpyrazone.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Sulfinpyrazone.Approved
IdelalisibThe serum concentration of Sulfinpyrazone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Sulfinpyrazone can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Sulfinpyrazone.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Sulfinpyrazone.Approved
IndinavirThe metabolism of Sulfinpyrazone can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
IrbesartanThe metabolism of Sulfinpyrazone can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
IsavuconazoniumThe metabolism of Sulfinpyrazone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Sulfinpyrazone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sulfinpyrazone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Sulfinpyrazone.Approved
KetoconazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
LapatinibThe metabolism of Sulfinpyrazone can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Sulfinpyrazone.Approved
LeflunomideThe metabolism of Sulfinpyrazone can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Sulfinpyrazone.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Sulfinpyrazone.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Sulfinpyrazone.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Sulfinpyrazone.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Sulfinpyrazone.Approved
LopinavirThe metabolism of Sulfinpyrazone can be decreased when combined with Lopinavir.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Sulfinpyrazone.Approved
LovastatinThe metabolism of Sulfinpyrazone can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Sulfinpyrazone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Sulfinpyrazone can be increased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Sulfinpyrazone.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Sulfinpyrazone.Approved, Illicit
MifepristoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Sulfinpyrazone.Approved
MitotaneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
ModafinilThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Sulfinpyrazone.Approved
NafcillinThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sulfinpyrazone.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
NefazodoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Sulfinpyrazone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Sulfinpyrazone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sulfinpyrazone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Sulfinpyrazone can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Sulfinpyrazone.Approved
NilotinibThe metabolism of Sulfinpyrazone can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Sulfinpyrazone.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Sulfinpyrazone.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
OlaparibThe metabolism of Sulfinpyrazone can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Sulfinpyrazone.Approved
OmeprazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Sulfinpyrazone can be increased when it is combined with Osimertinib.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
PalbociclibThe serum concentration of Sulfinpyrazone can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sulfinpyrazone.Approved
PentobarbitalThe metabolism of Sulfinpyrazone can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenindioneThe metabolism of Phenindione can be decreased when combined with Sulfinpyrazone.Approved
PhenobarbitalThe metabolism of Sulfinpyrazone can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Sulfinpyrazone.Approved
PhenytoinThe metabolism of Sulfinpyrazone can be increased when combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Sulfinpyrazone.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Sulfinpyrazone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Sulfinpyrazone.Approved
PosaconazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Sulfinpyrazone.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Sulfinpyrazone.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
PrimidoneThe metabolism of Sulfinpyrazone can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Sulfinpyrazone.Approved
PyrimethamineThe metabolism of Sulfinpyrazone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Sulfinpyrazone.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Sulfinpyrazone.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Sulfinpyrazone.Approved
RabeprazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Sulfinpyrazone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Sulfinpyrazone.Approved
RifabutinThe metabolism of Sulfinpyrazone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sulfinpyrazone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sulfinpyrazone can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
RitonavirThe metabolism of Sulfinpyrazone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Sulfinpyrazone.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
RosiglitazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Rosiglitazone.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Sulfinpyrazone.Approved, Vet Approved
SaquinavirThe metabolism of Sulfinpyrazone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Sulfinpyrazone.Approved
SecobarbitalThe metabolism of Sulfinpyrazone can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Sulfinpyrazone.Approved
SildenafilThe metabolism of Sulfinpyrazone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Sulfinpyrazone.Approved
SiltuximabThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sulfinpyrazone can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Sulfinpyrazone.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Sulfinpyrazone.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Sulfinpyrazone.Experimental
St. John's WortThe serum concentration of Sulfinpyrazone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Sulfinpyrazone can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Sulfinpyrazone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Sulfinpyrazone.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Sulfinpyrazone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Sulfinpyrazone.Approved
TelaprevirThe metabolism of Sulfinpyrazone can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Sulfinpyrazone can be decreased when combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Sulfinpyrazone.Approved
TeriflunomideThe metabolism of Sulfinpyrazone can be decreased when combined with Teriflunomide.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Sulfinpyrazone.Approved
TiclopidineThe metabolism of Sulfinpyrazone can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Sulfinpyrazone.Approved
TocilizumabThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Sulfinpyrazone can be decreased when combined with Tolbutamide.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Sulfinpyrazone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Sulfinpyrazone.Approved
TrimethoprimThe metabolism of Sulfinpyrazone can be decreased when combined with Trimethoprim.Approved, Vet Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Sulfinpyrazone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Sulfinpyrazone.Approved
Valproic AcidThe metabolism of Sulfinpyrazone can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Sulfinpyrazone can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Sulfinpyrazone.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Sulfinpyrazone.Approved
VenlafaxineThe metabolism of Sulfinpyrazone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Sulfinpyrazone can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Sulfinpyrazone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Sulfinpyrazone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Sulfinpyrazone.Approved
VoriconazoleThe metabolism of Sulfinpyrazone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Sulfinpyrazone.Approved
ZafirlukastThe metabolism of Sulfinpyrazone can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Sulfinpyrazone.Approved
ZiprasidoneThe metabolism of Sulfinpyrazone can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM04AB02
AHFS Codes
  • 40:40.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9961
Blood Brain Barrier+0.9776
Caco-2 permeable-0.5583
P-glycoprotein substrateNon-substrate0.9163
P-glycoprotein inhibitor INon-inhibitor0.858
P-glycoprotein inhibitor IINon-inhibitor0.6257
Renal organic cation transporterNon-inhibitor0.8111
CYP450 2C9 substrateNon-substrate0.5504
CYP450 2D6 substrateNon-substrate0.8878
CYP450 3A4 substrateSubstrate0.5146
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6332
Ames testNon AMES toxic0.6195
CarcinogenicityNon-carcinogens0.6932
BiodegradationNot ready biodegradable0.9577
Rat acute toxicity3.0218 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9712
hERG inhibition (predictor II)Non-inhibitor0.8418
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Apo-Sulfinpyrazone 200 mg Tablet0.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point136-137 °CPhysProp
water solubility31.2 mg/LNot Available
logP2.30HANSCH,C ET AL. (1995)
pKa3.25SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.323 mg/mLALOGPS
logP2.92ALOGPS
logP3.19ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area57.69 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity113.62 m3·mol-1ChemAxon
Polarizability42.15 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassNot Available
Direct ParentBenzene and substituted derivatives
Alternative Parents
Substituents
  • 1,3-dicarbonyl compound
  • Pyrazolidinone
  • Monocyclic benzene moiety
  • Pyrazolidine
  • Sulfoxide
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Sulfinyl compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P: Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. [PubMed:10917554 ]
  2. Morrow CS, Smitherman PK, Diah SK, Schneider E, Townsend AJ: Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J Biol Chem. 1998 Aug 7;273(32):20114-20. [PubMed:9685354 ]
  3. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523 ]
  4. Depeille P, Cuq P, Mary S, Passagne I, Evrard A, Cupissol D, Vian L: Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol Pharmacol. 2004 Apr;65(4):897-905. [PubMed:15044619 ]
  5. Raggers RJ, van Helvoort A, Evers R, van Meer G: The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J Cell Sci. 1999 Feb;112 ( Pt 3):415-22. [PubMed:9885294 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523 ]
  2. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P: Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. [PubMed:10917554 ]
  3. Morrow CS, Smitherman PK, Townsend AJ: Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol Carcinog. 2000 Nov;29(3):170-8. [PubMed:11108662 ]
  4. Ito K, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, Cole SP: Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem. 2001 Oct 12;276(41):38108-14. Epub 2001 Aug 10. [PubMed:11500505 ]
  5. Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, Benet LZ: Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology. 2002;64(3):126-34. [PubMed:11834888 ]
  6. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A: Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol. 2007 Feb;18(2):430-9. Epub 2007 Jan 17. [PubMed:17229912 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Transporter activity
Specific Function:
FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds saturated long-chain fatty acids with a high affinity, but binds with a lower affinity to unsaturated long-chain fatty acids. FABP2 may also help maintain energy homeostasis by functioning as a lipid sensor.
Gene Name:
FABP2
Uniprot ID:
P12104
Molecular Weight:
15207.165 Da
References
  1. Rowland A, Knights KM, Mackenzie PI, Miners JO: Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metab Dispos. 2009 Jul;37(7):1395-403. doi: 10.1124/dmd.109.027656. Epub 2009 Apr 27. [PubMed:19398502 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7. [PubMed:11581266 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [PubMed:12036927 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name:
ABCC5
Uniprot ID:
O15440
Molecular Weight:
160658.8 Da
References
  1. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P: Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7476-81. [PubMed:10840050 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4) and N-ethylmaleimide S-glutathione (NEM-GS).Isoform 2: Inhibits TNF-alpha-mediated apoptosis through blocking one or more caspases.
Gene Name:
ABCC6
Uniprot ID:
O95255
Molecular Weight:
164904.81 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P: Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. [PubMed:10917554 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, Benet LZ: Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology. 2002;64(3):126-34. [PubMed:11834888 ]
  2. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P: Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. [PubMed:10917554 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23